human leukemic monocyte lymphoma cell line u937 (BioResource International Inc)
Structured Review

Human Leukemic Monocyte Lymphoma Cell Line U937, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leukemic monocyte lymphoma cell line u937/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Hesperetin Induces Autophagy and Delayed Apoptosis by Modulating the AMPK/Akt/mTOR Pathway in Human Leukemia Cells In Vitro"
Article Title: Hesperetin Induces Autophagy and Delayed Apoptosis by Modulating the AMPK/Akt/mTOR Pathway in Human Leukemia Cells In Vitro
Journal: Current Issues in Molecular Biology
doi: 10.3390/cimb45020102
Figure Legend Snippet: Effect of hesperetin on human leukemic cell viability. HL-60 and U937 cell lines (4 × 10 4 cells/mL) were treated with hesperetin at 0, 12.5, 25, 50, and 100 µM for 24 h ( A ) and 48 h ( B ). Cell viability was evaluated using a CCK-8 assay. The Y -axis indicates the percentage of cell survival, and the X -axis indicates various concentrations of hesperetin. The mean ± SD of the three independent experiments performed in triplicate are shown. * p < 0.05; ** p < 0.01; *** p < 0.001 vs. the control group; ns, not significant; the results are representative of three independent experiments.
Techniques Used: CCK-8 Assay, Control
Figure Legend Snippet: Effects of hesperetin compounds on apoptosis and cell cycle arrest of U937 cells. ( A ) U937 cell apoptosis was analyzed at 24 and 48 h by flow cytometry with annexin V-FITC/PI staining to distinguish early apoptotic (annexin V-FITC positive, PI negative; Q4-1 and Q4) from late apoptotic or necrotic cells (Annexin V-FITC positive, PI positive; Q2-1 and Q2). ( B ) The cell cycle was assessed using flow cytometry in U937 cells with or without hesperetin treatment. ( C ) U937 cells were treated with hesperetin at 0, 12.5, 25, 50, and 100 µM for 48 h. Cleaved-PARP-1, Bcl-2, Bax, and GAPDH expressions were analyzed with Western blotting by using the cell lysates. The mean ± SD of the three independent experiments performed in triplicate are shown. * p < 0.05; ** p < 0.01; *** p < 0.001 vs. the control group; ns, not significant; the results are representative of three independent experiments.
Techniques Used: Flow Cytometry, Staining, Western Blot, Control
Figure Legend Snippet: Effects of hesperetin on autophagy in U937 cells. ( A ) To evaluate the change in the number of AVOs in cells treated with hesperetin, the cells were treated with different concentrations of hesperetin at 24 and 48 h. Next, the cells were stained with acridine orange (1 μg/mL) at 37 °C for 15 min in the dark. The cells were analyzed using a FACScan flow cytometer. The data were analyzed using BD Cell Quest software. ( B ) LC3-I/II, Beclin-1, Atg5, p62, and GAPDH protein expression for 24 and 48 h ( C ) were analyzed with Western and semiquantified in representative results of the same pattern from three independent experiments are shown. ( D ) U937 cells were exposed to the indicated concentration of hesperetin in the presence or absence of autophagy inhibitor 3-MA (left panel) or Baf-A1 (right panel) for 24 h. Cell viability was assessed using the CCK-8 assay. The mean ± SD of the three independent experiments performed in triplicate are shown. * p < 0.05; ** p < 0.01; *** p < 0.001 vs. the control group; ns, not significant; the results are representative of three independent experiments.
Techniques Used: Staining, Flow Cytometry, Software, Expressing, Western Blot, Concentration Assay, CCK-8 Assay, Control
Figure Legend Snippet: Effect of hesperetin on the AMPK/Akt/mTOR signaling pathway in U937 cells. U937 cells (5 × 10 5 ) were treated with hesperetin at 0, 12.5, 25, 50, and 100 μM for 24 h ( A ) and 48 h ( B ). The expression of phospho-AMPK Thr172 , AMPK, phospho-mTOR Ser2448 , mTOR, Phospho-Akt Ser473 , Akt and GAPDH was analyzed with Western blotting and semiquantified; representative results of the same pattern from three independent experiments are shown. The mean ± SD of the three independent experiments performed in triplicate are shown. * p < 0.05; ** p < 0.01; *** p < 0.001 vs. the control group; ns, not significant; the results are representative of three independent experiments.
Techniques Used: Expressing, Western Blot, Control
Figure Legend Snippet: Schematic diagram of hesperetin molecular mechanism in leukemia cells. Hesperetin modulates AMPK/Akt/mTOR signaling and induces autophagy and delayed apoptosis by regulating the AMPK/Akt/mTOR pathway through AMPK activation, Akt and mTOR downregulation, inactivating and activating various target proteins, such as cleaved-PARP-1, Bcl-2, Bax, LC3-I/II, Beclin-1, Atg5, and p62; hesperetin promoted cell death in the human leukemic cell line U937 by inducing a low degree of slight apoptosis, cell cycle arrest, and autophagy, which increases the anticancer effect on leukemia (created with BioRender.com).
Techniques Used: Activation Assay

